|
| Press Releases |
|
 |
|
| Friday, October 21, 2016 |
|
|
Nanobiotix's Partner, PharmaEngine, Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia |
| NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. more info >> |
|
| Tuesday, October 4, 2016 |
|
|
Nanobiotix Strengthens U.S. Leadership with Appointments of Head of U.S. Clinical Development and Director of Investor Relations |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as the Head of U.S. Clinical Development and Noel Kurdi as the Director of Investor Relations. more info >> |
|
| Tuesday, September 20, 2016 |
|
|
Bpifrance Grants Nanobiotix a 2M EUR Interest-free Loan to Support Final Development Stage of Lead Product, NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that Bpifrance has awarded the Company an interest-free loan of EUR 2M for Innovation (pret a taux zero pour l'Innovation - PTZI). more info >> |
|
| Wednesday, September 14, 2016 |
|
|
Nanobiotix Announces Submission for First Market Approval of Lead Product NBTXR3 in Europe |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has filed for market approval (CE Marking) in Europe for its lead product, a first-in-class radio-enhancer, NBTXR3. more info >> |
|
| Thursday, July 7, 2016 |
|
|
Nanobiotix Reports Successful Results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer |
| NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced positive results from a Phase I/II clinical trial of its lead product, NBTXR3, for the treatment of locally advanced cancers of the oral cavity, tongue or oropharynx (head and neck cancer, or H&N) in frail and elderly patients. more info >> |
|
| Tuesday, May 31, 2016 |
|
|
Nanobiotix Establishes Promising Preclinical Proof-of-Concept in Immuno Oncology |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that the Company has established preliminary preclinical proof-of-concept (POC) with the lead product NBTXR3 for its new program in Immuno Oncology (IO). more info >> |
|
| Friday, April 29, 2016 |
|
|
Nanobiotix: 2015 Annual Results |
| Nanobiotix (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces its audited consolidated results for the fiscal year ended December 31, 2015. more info >> |
|
| Tuesday, January 5, 2016 |
|
|
Nanobiotix Starts a New Research Program, in Immuno Oncology, with Its Lead Product NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology. more info >> |
|
| Thursday, July 2, 2015 |
|
|
Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 |
| Nanobiotix (Euronext: NANO), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has been authorized to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3. more info >> |
|
| Wednesday, June 10, 2015 |
|
|
Nanobiotix Reports Positive Preliminary Results in Head and Neck Cancer Phase I/II Clinical Trial with NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
西藏智汇矿业登陆港股：从高原走向国际 独特资源禀赋释放长期增长潜力
Dec 19, 2025 16:15 HKT/SGT
|
|
|
西藏智匯礦業登陸港股：從高原走向國際 獨特資源稟賦釋放長期增長潛力
Dec 19, 2025 15:35 HKT/SGT
|
|
|
A New Benchmark for Specialized Technology Stocks in Hong Kong! CiDi's Listing Marks a New Chapter in Commercial Intelligent Driving
Dec 19, 2025 11:30: JST
|
|
|
A New Benchmark for Specialized Technology Stocks in Hong Kong! CiDi's Listing Marks a New Chapter in Commercial Intelligent Driving
Dec 19, 2025 10:30 HKT/SGT
|
|
|
トヨタ、米国生産トヨタ車の26年からの日本導入を検討
Dec 19, 2025 10:00: JST
|
|
|
Air T, Inc. Announces Closing of Regional Express Acquisition
Dec 19, 2025 06:10 HKT/SGT
|
|
|
MHI Participates in Demonstration Testing of Vehicle-Infrastructure Integration System for Autonomous Buses in Shimotsuke City
Dec 19, 2025 3:24 JST
|
|
|
NEC and emaratech Collaborate on Biometric Smart Gates Supporting UAE Airport Operations
Dec 19, 2025 3:06 JST
|
|
|
Fujitsu to showcase mobility and physical AI tech at CES 2026
Dec 19, 2025 2:42 JST
|
|
|
Kirin and Fujitsu elucidate a novel gut-brain axis mechanism of citicoline for the first time worldwide through AI-based analysis and experimental validation leveraging drug discovery DX technology
Dec 19, 2025 2:06 JST
|
|
|
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Released Their Fourth Collaborative Musical Work with Sound Wellness Lab (Della): "Precious Metal Orchestra - A Musical Voyage through the Sound of Precious Metals for Christmas" now available for streaming.
Dec 18, 2025 22:00 JST
|
|
|
Focus Graphite Announces Final Results From 2022 Drill Program at Lac Tetepisca; West Limb Extends Mineralized Strike to 8 KM
Dec 18, 2025 18:09 HKT/SGT
|
|
|
Spritzer MerryLand Returns This Year-End, Bringing Magical Festive Cheer to Taiping
Dec 18, 2025 17:44 HKT/SGT
|
|
|
臥安機器人今起招股 獲9家豪華基石陣容超7億港元認購 募集資金超10億港元
Dec 18, 2025 14:09 HKT/SGT
|
|
|
卧安机器人今起招股 获9家豪华基石阵容超7亿港元认购 募集资金超10亿港元
Dec 18, 2025 14:09 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
